Nat Commun: Developed a new immunotherapy to fight cancer.

September 12, 2020 /--- In a new study, Sophie Lucas of the Duff Institute at the University of Leuven in Belgium and her team successfully mediated a molecule that blocks the immune system's resistance to cancer.
specifically, they selectively blocked regulatory T lymphocytes (Tregs) from producing TGF-beta1 using antibodies directed at the GARP:TGF-beta1 complex (a compound formed by the protein GARP and TGF-beta1), thereby inducing resistance to the withdrawal of mouse tumors originally produced by anti-PD-1 antibody immunotherapy.
they found that the new immunotherapy could increase the role of another well-known but not always effective immunotherapy, known as anti-PD-1 antibody immunotherapy, and that it made it possible for tumors to subside.
, a promising finding in the fight against cancer, was published on September 11, 2020 in the journal Nature Communications under the title "Selective resedion of TGF-beta-1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer".
photo from Nature Communications, 2020, doi:10.1038/s41467-020-17811-3.
The researchers found that the combined blocking of GARP:TGF-beta1 and blocking is immuno-mediated and does not require Fc-R-dependent function to enhance the effect function of anti-tumor CD8-T cells, but does not enhance immune cell immersion or Treg cell rejection in tumors.
, they found Treg cells expressing GARP in one-third of human melanoma metastasis tumors, and there is evidence that they produce TGF-beta1.
these results suggest that anti-GARP:TGF-beta-1 antibodies may overcome resistance to PD-1/PD-L1 blocking in cancer patients by selectively blocking TGF-beta 1 produced by Tumor-active Treg cells.
cancer immunotherapy is to manipulate the body's naturally occurring immune response to fight cancer.
, these immune responses are blocked by cells or molecules and do not kill cancer cells, allowing tumors to camp and grow.
2004, Sophie Lucas, a researcher at the Duff Institute at the University of Leuven, began studying the function of blocking immune defenses in tumors to understand the function of immunosuppressive cells, which block immune responses in the body.
her goal is to identify and remove them, thereby stimulating antibodies to work on the tumor.
identified as Treg cells: highly immunosuppressive cells in cancer patients.
in 2009, Professor Lucas discovered the molecule GARP, located on the surface of the Treg cell.
2018, Professor Lucas finally managed to understand the role of GARP: the molecule acted as a messenger for Treg cells, blocking the immune response by sending signals.
she is developing a tool (anti-GARP antibody) to heal and prevent this messenger molecule from sending its blocking signals.
important findings were published in the November 23, 2018 issue of The Science Journal (Science, 2018, doi:10.1126/science.aau2909).
the new study, Professor Lucas and her team published their first test results.
these tests are promising.
they successfully mesothaded Treg cells in cancer mice with anti-GARP: TGF-beta-1 antibodies.
if the messenger molecule (GARP: TGF-beta1) is completely completely completelyied, the immune response will not be blocked and cancer cells can be eliminated again.
as long as the anti-GARP: TGF-beta-1 antibody is combined with another mature immunotherapy (anti-PD1 antibody), the tumor will quickly subside.
, Lucas's team combined two complementary immunotherapy therapies to act on the immune system in different ways to improve the effectiveness of cancer treatment.
and it works well! These same tests in humans may eventually provide a more effective treatment for cancer.
(bioon.com) Reference: 1.New immunotherapy to beat cancerégoire de Streel et al. Selective resedion of TGF-beta 1 producted by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. Nature Communications, 2020, doi:10.1038/s41467-020-17811-3.